Tevogen Inc. filed a Form S-3 registration statement with the SEC on November 16, 2026, covering the resale of up to 1,029,126 shares of common stock by a single selling stockholder.
Key Highlights
- Shares registered: Up to 1,029,126 shares of common stock, par value $0.0001 per share, offered entirely by the Selling Stockholder.
- Source of shares: Shares were issued as payment of outstanding principal and accrued interest under a Loan Agreement dated June 6, 2024, as amended October 27, 2026.
- No company proceeds: Tevogen Inc. will not receive any proceeds from the sale of shares; the Selling Stockholder retains all sale proceeds.
- Registration costs: Tevogen Inc. will bear all costs, expenses, and fees in connection with the registration of the shares.
- Stock price reference: The closing price of common stock on November 13, 2026 was $6.00, according to the filing.
- Company classification: Tevogen Inc. is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Tevogen Inc. Registers Loan-Repayment Shares for Resale Under S-3
Tevogen Inc. (NASDAQ:TVGN), based in Warren, New Jersey, filed a Form S-3 registration statement on November 16, 2026, to register up to 1,029,126 shares of its common stock for resale by a single selling stockholder. According to the filing, the shares were issued to the Selling Stockholder in two categories: shares issued in November 2026 as payment of outstanding principal under the company's Loan Agreement, referred to as "Principal Shares," and shares issued as payment of accrued interest both before and in November 2026, referred to as "Interest Shares."
The underlying Loan Agreement was originally dated June 6, 2024, and was subsequently amended by the First Amendment to Loan Agreement dated October 27, 2026, as the filing describes. Tevogen Inc. stated that it is not selling any shares of common stock under this prospectus and will not receive any proceeds from the Selling Stockholder's sales. The Selling Stockholder will bear all commissions and discounts, if any, attributable to the sale, while the company will bear all registration-related costs, expenses, and fees.
The filing states that the Selling Stockholder may sell shares from time to time through ordinary brokerage transactions or other means described in the "Plan of Distribution" section of the prospectus. Shares may be sold at fixed prices, at prevailing market prices, at prices related to the prevailing market price, or at negotiated prices. The prospectus notes that the common stock is listed on Nasdaq under the symbol "TVGN," and that the closing price on November 13, 2026 was $6.00. The filing also notes that the registration statement is subject to completion and that shares may not be sold until it becomes effective.
What Was Disclosed
Tevogen Inc. filed an S-3 registration statement to enable the resale of up to 1,029,126 shares issued to a lender as repayment of principal and interest under an amended loan agreement. The company will receive no proceeds from these sales.



Please wait processing your request...